BCL2 and breast cancer: Alterations in the BCL-2 protein family, with overexpression of anti-apoptotic members (e.g., BCL-2, BCL-xL) and downregulation of pro-apoptotic counterparts (e.g., BAX, PUMA), contribute to apoptosis evasion in breast cancer.